Nuveen
AMPH icon

Nuveen’s Amphastar Pharmaceuticals AMPH Stock Holding History

Nuveen’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
88,397
+11,802
+15% +$238K ﹤0.01% 2631
2026
Q1 		$1.5M Buy
76,595
+494
+0.6% +$12.1K ﹤0.01% 2383
2025
Q4 		$2.04M Sell
76,101
-1,602
-2% -$41.3K ﹤0.01% 2288
2025
Q3 		$2.07M Sell
77,703
-3,439
-4% -$88.8K ﹤0.01% 2281
2025
Q2 		$1.86M Sell
81,142
-14,523
-15% -$360K ﹤0.01% 2335
2025
Q1 		$2.77M Hold
95,665
– – ﹤0.01% 2189
2024
Q4 		$3.55M Sell
95,665
-112,307
-54% -$5.14M ﹤0.01% 2135
2024
Q3 		$10.1M Sell
207,972
-93,617
-31% -$4.11M ﹤0.01% 1599
2024
Q2 		$12.1M Buy
301,589
+114,098
+61% +$4.73M ﹤0.01% 1473
2024
Q1 		$8.23M Sell
187,491
-2,356
-1% -$122K ﹤0.01% 1722
2023
Q4 		$11.7M Sell
189,847
-164,112
-46% -$8.62M ﹤0.01% 1494
2023
Q3 		$16.3M Sell
353,959
-20,560
-5% -$1.12M 0.01% 1163
2023
Q2 		$21.5M Buy
374,519
+56,195
+18% +$2.49M 0.01% 1026
2023
Q1 		$11.9M Sell
318,324
-65,681
-17% -$2.15M ﹤0.01% 1372
2022
Q4 		$10.8M Sell
384,005
-32,602
-8% -$947K ﹤0.01% 1439
2022
Q3 		$11.7M Sell
416,607
-174,217
-29% -$5.69M ﹤0.01% 1383
2022
Q2 		$20.6M Buy
590,824
+114,149
+24% +$4.07M 0.01% 1031
2022
Q1 		$16.9M Buy
476,675
+93,448
+24% +$2.65M 0.01% 1296
2021
Q4 		$8.26M Buy
383,227
+9,175
+2% +$188K ﹤0.01% 1811
2021
Q3 		$6.87M Sell
374,052
-45,085
-11% -$883K ﹤0.01% 2041
2021
Q2 		$8.45M Buy
419,137
+243,749
+139% +$4.59M ﹤0.01% 1969
2021
Q1 		$3.21M Sell
175,388
-11,172
-6% -$208K ﹤0.01% 2385
2020
Q4 		$3.75M Sell
186,560
-18,626
-9% -$362K ﹤0.01% 2219
2020
Q3 		$3.85M Buy
205,186
+20,651
+11% +$416K ﹤0.01% 2055
2020
Q2 		$4.14M Buy
184,535
+46,580
+34% +$853K ﹤0.01% 2003
2020
Q1 		$2.05M Sell
137,955
-390
-0.3% -$6.79K ﹤0.01% 2173
2019
Q4 		$2.67M Sell
138,345
-165,026
-54% -$3.17M ﹤0.01% 2306
2019
Q3 		$6.02M Sell
303,371
-271,412
-47% -$5.65M ﹤0.01% 1863
2019
Q2 		$12.1M Buy
+574,783
New +$12M ﹤0.01% 1477

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's AMPH Position: Q2 2026 in Review

Nuveen increased its Amphastar Pharmaceuticals (AMPH) stake by 15% in Q2 2026, buying an estimated $238K and bringing the position to 88,397 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

Nuveen first reported a position in AMPH in Q2 2019 and has held it in 29 quarters since. The position peaked at $21.5M in Q2 2023. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Nuveen held 88,397 shares of Amphastar Pharmaceuticals worth $1.78M as of Q2 2026.
  • Nuveen bought 11,802 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $238K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2631 holding.
  • Nuveen first reported a position in Amphastar Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Amphastar Pharmaceuticals position peaked at $21.5M in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.